EAE/Peptide Mouse Models for Multiple Sclerosis (MS)

EAE Peptide Mouse Models for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic neurodegenerative and inflammatory disease of the central nervous system (CNS) that represents one of the most prevalent human autoimmune diseases. MS is a complex disease with heterogeneous clinical and pathological phenotypes. Clinically, MS may present as a relapsing-remitting disease or with steady progressive neurological disability.

Mouse models of experimental autoimmune encephalomyelitis (EAE) acquired inflammatory and demyelinating autoimmune disease have been investigated extensively.  Washington Biotechnology, Inc. has validated an EAE mouse model for each of the two phenotypes:

Acute and Relapsing EAE

·         80% prevalence among MS patients

·         Pathologically associated with the formation of focal inflammatory demyelinating lesions in the white matter

·         WBI In Vivo Model: PLP139-151 peptide-induced EAE Model in SJL Mice

Chronic Progressive EAE

·         20% prevalence among MS patients. 

·         Pathologically associated with a widespread axonal damage in the normal appearing white matter and massive demyelination in the grey matter, particularly in the cortex.

·         WBI In Vivo Model: MOG35-55 peptide-induced EAE Model in C57BL/6 Mice

PLP _139-151 Peptide-induced EAE Model in SJL Mice

PLP_139-151 peptide-induced EAE Model in SJL Mice is known to be a well-suited tool to experimentally address mechanisms that cause the relapsing-remitting autoimmune pathology of the CNS of MS patients and to evaluate the efficacy of test compounds for curing or preventing MS.

PLP_139-151 is extensively expressed in the CNS and causes lesions that resemble many features of MS and clinically show symptoms of the relapsing-remitting disease phenotype. Many other physical features including limp tail, hind and/or front legs wakening or complete paralysis are observed and scores as indexes of disease severity.

Washington Biotechnology, Inc. has validated in SJL mice an EAE model that demonstrates relapsing-remitting disease episodes over a 30 day period, using Dexamethasone as positive prophylactic and therapeutic control (see table and graph below).

Our PLP- induced EAE Model features clearly defined disease parameters and scoring in reliable protocols for the prophylactic or therapeutic efficacy testing.

MOG_35-55 peptide-induced EAE Model in C57BL/6 Mice

The administration of myelin protein derived peptides such as myelin oligodendrocyte glycoprotein 35-55 (MOG_35-55) to susceptible mice such as the C57BL/6 mice strain has been shown to induce EAE. MOG_{35-55 is} expressed in the CNS and causes lesions that resemble many features of MS and show clinical symptoms of the progressive chronic disease phenotype. Many other physical features including limp tail, hind and/or front legs wakening or complete paralysis are observed and scored as indexes of disease severity.

MOG_35-55 peptide-induced EAE Model in C57BL/6 mice is known to be a well-suited tool to experimentally addressing mechanisms that cause the progressive chronic autoimmune pathology of the CNS of MS patients and for evaluating the efficacy of test compounds for curing or preventing MS. 

Washington Biotechnology, Inc. has validated in C57BL/6 mice an EAE model that shows a progressive chronic disease phenotype using Dexamethasone as positive prophylactic or therapeutic control (see table and graph below).

Our model provides clearly defined efficacy for both prophylactic and therapeutic treatments with Dexamethasone.

The WBI MOG – EAE Model incorporates careful attention to study procedures, reagent quality and clear definition of disease parameters and scoring to provide reliable and cost-effective studies for assessment of compound efficacy.

Initiation of DXM administration as positive prophylactic control

Initiation of DXM administration as positive therapeutic control